The trace characterization of physiologically active substances with low molecular weight (e.g., steroids, catecholamines, prostaglandins, and oligopeptides), which are classiˆed as``haptens'', is an important subject in clinical analysis, and competitive immunoassays have conventionally been used for this purpose. However, the subfemtomole-range determination of haptens is very di‹cult, as the sensitivity of competitive immunoassays is essentially limited by the a‹ni-ty of the anti-hapten antibodies that barely reaches the range of 10 11 (l/mol) as the a‹nity constant (K a ). Although a noncompetitive``immunometric assay'' format, the two-site immunometric assay (sandwich immunoassay), enables even subattomole-range measurements of macromolecules such as proteins, this principle can not be directly applied to haptens, as their low molecular mass prohibits simultaneous binding by two antibody molecules. To overcome such limitations, we are required either to create artiˆcial antibodies showing ultrahigh a‹nity to haptens by protein engineering of antibody molecules (``antibody engineering'') or establishment of novel immunometric assay formats applicable to haptens. This review surveys the background and recent approach for subfemtomole-range determination of haptens using novel immunometric assay methods. Our studies for the development of hapten immunometric assays are also described.
ハプテンイムノアッセイの感度
(A) 125 I-labeled 25D 3 (molar ratio 1：1) is used as the labeled antigen at the concentration (A) of 2 pmol/l under the 50％ saturation (B 0 /T＝50％) condition (a-e), in combination with the antibody whose Kd is (a) 1.0× 10 -9 , (b) 1.0×10 -10 , (c) 1.0×10 -11 , (d) 1.0×10 -12 , or (e) 1.0×10 -15 mol /l. (B) The antibody (K d ＝1.0×10 -15 mol/l) is used under the 50％ saturation (B 0 /T＝50％) condition (a and b), in combination with (a) an acridinium ester-labeled 25D 3 at the concentration (A) is 2.0×10 -2 pmol/l or (b) with an enzyme-labeled 25D 3 (molar ratio 1：1) at the concentration (A) is 8.0×10
-5 pmol/l. All the competitive antigen-antibody reactions (both A and B) are assumed to be carried out in a 500 ml assay medium. The abbreviations, B, B 0 , T are as follows: B: the signal intensity due to the bound labeled-antigen at any unlabeled antigen concentration, B0: the signal intensity due to the bound labeled-antigen when the unlabeled antigen concentration is zero, T: the signal intensity due to the total labeled-antigen used in the competitive reaction.
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M r 400.6）をモデルハプテンとして，標準曲線をシ
, 10 The improved single-antibody immunometric assays (SA-IMAs) (i) separating immune complex and excess labeled antibodies using hapten-immobilized a‹nity-column or based on the diŠerence in their physical property and (ii) its variation based on masking of unoccupied antibodies by immunoreactive macromolecules that work as`p aratope blocker'' followed by selective capture and detection of the hapten-occupied antibodies. (C) The assays employing a probe molecule speciˆc to a hapten-antibody complex. 
定について各々 10 amol/assay, 50 amol/assay で， 125 I 標識抗原を用いる RIA に比べ 100 倍高感度であ った．これらのような低分子ペプチドのほかに，チ ロキシンの測定にも応用されている． 3-2-2. Solid-phase Immobilized Epitope Immunoassay 13) 前項と同様に標的ハプテンのアミ , 1 fg, 10 pg, 100 pg, or 100 ng) were incubated in 55 ml assay buŠer in a standard microplate at 37°C for 2 h. An aliquot of this solution (50 ml) was transferred to the 11-DC-BSA-coated plate, which were incubated for an additional hour at 37°C. An aliquot of the supernatant (45 ml) was mixed with the AttoPhos substrate solution (10 ml) and ‰uorescence intensity was measured. (B) The assay was performed as described above, but the aliquot of 11-DC-BSA-coated plate supernatant (45 ml) was instead transferred to the a-Id-coated (indirectly via an anti-mouse IgG antibody) standard microplate. After incubation at 37°C for 30 min, the plate was washedˆve times. Water (90 ml) and AttoPhos substrate solution (10 ml) were added to each well and ‰uorescence intensity was measured. (C) The assay was performed according to the optimized procedure described in Fig.  13 . Solutions of scFv-ALP (200 fmol/10 ml/well) and an 11-DC standard (0-100 ng/10 ml/well) were incubated in a half-area microplate at 37°C for 2 h. A solution of the b-Id (6 mg/10 ml/well) was added to the mixture and incubated at 37°C for 20 min with continuous shaking. An aliquot of this solution (25 ml) was mixed with a suspension of the second antibody-coated beads in a standard microplate. After incubation at 37°C for 15 min with continuous shaking, beads were removed by magnetic separation. An aliquot of the supernatant (30 ml) was transferred to the a-Id-coated (indirectly via an anti-mouse IgG antibody) half-area microplate and incubated at 37°C for 30 min. After washingˆve times, bound ALP activity was measured ‰uorometrically using AttoPhos substrate. 
